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ABG Arterial blood gas 
ACS Acute chest syndrome 
ACT Activated clotting time 
AHTR  Acute haemolytic transfusion reaction 
ASD Atrial septal defect 
BNP Brain natriuretic peptide 
CO Cardiac output 
CVA Cerebrovascular Accident 
CPB Cardiopulmonary bypass 
CXR Chest X-ray 
DHTR  Delayed haemolytic transfusion reactions 
DRC Departmental research committee 
HDFN  Haemolytic disease in the foetus and new born 
Hb Haemoglobin 
HbF Foetal haemoglobin 
HbS Sickle haemoglobin 
Hct Haematocrit 
HR Heart rate 
ICU Intensive Care Unit 
LV Left ventricle 
NIRS  Near infra-red spectroscopy 
NO Nitric Oxide 
PAF Platelet activating factor 
PAP Pulmonary artery pressure 
PH Pulmonary Hypertension 
PS Phosphatydil serine 
REC Research ethics committee 
ROS Reactive oxygen species 
RR Risk Ratio 
SCA Sickle cell anaemia 
SCD Sickle cell disease 
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SCT  Sickle cell trait 
VOC Vaso-occlusive Crisis 
TF Tissue factor 
TLC Total Lung capacity 
TRV Tricuspid regurgitant jet velocity 
UCT University of Cape Town 






















































 1. Background 
Haemoglobin is the principal oxygen transporter in human red blood cells.  Sickle cell disease (SCD) is a 
common genetic mutation resulting in the variant Haemoglobin S (HbS).  Under certain conditions the 
HbS undergo a process described as sickling due to polymerization of the haemoglobin molecule, 
precipitating diffuse cellular injury with a variable clinical presentation and potentially life threatening 
complications.  Two types exist:  Sickle cell trait (heterozygous), or Sickle cell disease (homozygous), the 
latter being the more severe form where the majority of circulating haemoglobin is HbS.1,2 
The incidence of SCD in South Africa is low, although in Sub-Saharan Africa (SSA) it occurs at its 
highest frequency. Up to 300 000 babies are born with Sickle cell trait (SCT) annually. Due to 
immigration from the SSA countries, the occurrence of patients with SCD presenting at facilities in South 
Africa is on the rise. The Haematology/Oncology Service at Red Cross War Memorial Children’s Hospital 
in Cape Town has seen a 300-400% increase in new patients with SCD between 2001-2010.3 
These patients may present for a range of surgical procedures, not necessarily related to their underlying 
disease.  Common procedures include adeno-tonsillectomy, splenectomy, orthopaedic procedures, neuro- 
and cardiac surgery.  The peri-operative period poses numerous risks to this already vulnerable patient 
population.  Major surgery, like cardiac surgery, has the highest potential to trigger the sickling process 
and its associated complications - adversely affecting patient outcome.1 Employing Cardiopulmonary 
bypass (CPB) during these procedures adds to the list of potential precipitants.4 
 
 2. Objective 
A 5-month-old baby with SCD recently presented for repair of a Ventricular septal defect (VSD), 
requiring cardiopulmonary bypass, at Red Cross War Memorial Children’s Hospital.   The importance of a 
thorough understanding of the pathophysiology of the disease and the need for careful planning in a 
multidisciplinary fashion was highlighted during the course of the initial surgery and subsequent redo 
surgery. 
This experience led to a detailed review of the literature on sickle cell disease and cardiac surgery in the 
paediatric population. Advances in research on the molecular basis of the disease process have sparked a 
surge of interest in this topic.1,2,5 A recent case series from Great Ormond Street Children’s Hospital in the 
United Kingdom discussed the management of 3 patients with SCD for correction of congenital cardiac 
lesions requiring cardiopulmonary bypass.4 Another case series published in Circulation 2010 involved a 
total of 21 paediatric patients for various corrective cardiac surgical procedures.6 Because of the relatively 
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low incidence of the disease, and highly specialised nature of cardiac surgery, very few large trials exist in 
this area.  Case series continues to prove a valuable resource to gain insight in the management of these 
cases, especially for patients requiring CPB.4 Review articles on the implications of SCD and anaesthesia 
were published in Paediatric Anaesthesia 2003 and Anaesthesiology 2004, which attest to the importance 
of this topic and the need for a thorough anaesthetic management plan in these high risk cases.1,2   
 
 3. Protocol 
Between 2004 and 2013 four patients with sickle cell haemoglobinopathy (two SCD and two SCT) 
required cardiac surgery at RCWMCH.  Two of these patients required redo-surgery for unrelated reasons, 
therefore, a total of six anaesthetics/surgeries (6 requiring CPB) were performed. 
Retrospective data collection from the files of these patients will be analysed:  patient demographics, 
medical background, type of surgery, pre- and intra-operative management, anaesthetic- surgical- and 
cardiopulmonary bypass-data, post-operative course, with particular attention to transfusion regimen 
instituted, occurrence of complications and adverse outcome. 
A descriptive review of the current literature will be conducted with the aim to provide recommendations 
on the optimal management of patients with underlying sickle cell disease requiring cardiac surgery.  
Patient details and personal information will not be disclosed.  Confidentiality will be maintained during 
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A critical review of the current literature on sickle cell disease with particular emphasis on the 
implications for paediatric patients presenting for cardiac surgery requiring cardio-pulmonary bypass will 
be conducted. 
 
2. Literature review strategy 
A literature search on Medline was conducted, using keywords: sickle cell disease, sickle cell anaemia, 
sickle cell trait, cardiopulmonary bypass, cardiac, anaesthesia and transfusion. Literature between 1995 
and 2014 were included. Research in adult and paediatric populations was reviewed with an emphasis on 
paediatric literature.  
 
3. Review and critical appraisal of literature 
In 1910 James B Herrick (Professor Of Medicine, Rush Medical College, 1861–1954) published the first 
detailed case report and description of sickle cell disease. This followed on an earlier description in 1902 
by M. Dresbach of an “elliptical, not circular” red blood corpuscle that was sampled from a student at the 
Ohio State University histology laboratory.  Since then it has been recognised that these “peculiar” red 
blood cells lead to vaso-occlusion and end organ damage as well as complex interactions with the vascular 
endothelium dysregulation of Nitric oxide (NO) balance and disruption of coagulation.1 
3.1 Genetics, Biochemistry and Pathophysiology 
	  
Sickle cell disease (SCD) is the most common inherited haematological disorder.2 A single point mutation 
on the gene coding for the β-globin chain of Haemoglobin (Hb) on chromosome 11, leads to the 
inheritance of mutant haemoglobin S (HbS).3,4  See figure 1. 
 
Figure 1: Sickle cell disease genotypes (5)	  Sickle	  cell	  disease	  (SCD)	  Sickle	  Cell	  Anaemia	  (SCA)	  Sickle	  Cell	  
Trait	  (SCT)	  Foetal	  Haemoglobin	  (HbF)	  Normal	  Haemoglobin	  (HbA)	  
 













The negatively charged, hydrophilic glutamic acid in HbA, is replaced by the neutrally charged non-polar, 
hydrophobic valine at position 6 on the β-globin chain of Hb to HbS.6–8 This substation alters its solubility 
and stability in certain conditions. 
Firstly, HbS solubility is decreased when deoxygenated and precipitates out of solution, forming long 
chains that distort or ‘sickle’ erythrocytes.  
Secondly, the loss of negative charge destabilise the HbS structure leading to accelerated denaturation and 
breakdown of the molecule, distorting the erythrocyte and predisposing it to haemolysis.9 Increased 
vascular inflammation and activation of the coagulation pathways are also involved in the clinical 
manifestation of SCD, as depicted in figure 2.4 The clinical conditions required to initiate erythrocyte 
sickling, such as hypoxia, hypothermia, acidosis and low flow states, are discussed in more detail later.  	  
 
Figure 2: Pathophysiology of sickle cell disease 
  
Vaso-occlusion and reperfusion ischemia injury: 
Vaso-occlusive crisis (VOC), or pain crisis is a common manifestation of SCD. HbS polymerisation leads 
to erythrocyte deformation and rigidity, making them less pliable than normal erythrocytes and prone to 
vascular and microcirculatory occlusion. Tissue ischemia ensues and upon restoration of blood flow, 
reperfusion injury occurs. This activates xanthine oxidases (XO) and free radical production, oxidant 
stress and release of platelet activating factor (PAF). Inflammatory stress and expression of cytokines and 
endothelial adhesion molecules worsen the cycle of ischemia and reperfusion, potentiating further tissue 
hypo-perfusion, erythrocyte sickling and endothelial inflammation. In particular adhesion molecules, such 












interaction responsible for cyclic vaso-occlusion of post-capillary venules, and ischemia-reperfusion 
injury of multiple organs.2 
Haemolytic anaemia and Nitric oxide depletion 
Polymerisation of HbS and erythrocyte sickling causes haemolysis and clinically significant anaemia.4 In 
addition, intravascular haemolysis compartmentalises haemoglobin and arginase-1 realising them into the 
plasma.  
Free plasma Hb generates reactive oxygen species (ROS) such as hydroxyl and superoxide radicals, which 
actively scavenge Nitric oxide (NO). NO is an essential regulator of vascular function, determining 
vasodilator tone, especially in the pulmonary vasculature. It also inhibits platelet activation and 
transcriptional nuclear factor-κB (NF-κB)-dependant expression of adhesion molecules. Due to rapid 
interaction with haemoglobin, the half-life of NO is exceptionally short, forming methaemoglobin and 
nitrate. Therefore, free plasma Hb potently inhibits NO signalling leading to NO resistance and endothelial 
dysfunction.1,4,10 
Arginase-1 metabolises the precursor of NO generation, L-Arginine, forming ornithine. NO production is 
subsequently decreased. The amount of NO bound to Hb (S-nitroso-haemoglobin) for transport from the 
pulmonary circulation to the microvasculature is also decreased, leading to further endothelial 
dysfunction.11 The ROS mentioned cause inflammatory damage to the vascular endothelium adding to the 
dysregulation of endothelial function. Recurrent haemolysis disrupts the regulation of NO availability in 
this fashion and may lead to Pulmonary Hypertension (PH).10,12 
 
Hypercoagulation 
A hypercoagulable state and thrombosis is well documented in SCD due to dysregulation of coagulation. 
In these individuals activation of coagulation pathway depends on multiple triggers and inhibitors to 
maintain haemostasis. NO is a potent inhibitor of platelet activation, but in SCD chronic NO depletion and 
arginine deficiency (the substrate for NO synthesis) favours platelet activation. Increased intracellular 
expression of platelet arginase (arginine consumption) and activation of tissue factor (TF) further 
potentiates platelet activation and hypercoagulability.1,13 Recurrent sickling produces sickle erythrocytes 
with high levels of phosphatydil serine (PS) expression on their membrane surface. With its highly 
negative charge, PS facilitates the assembly of clotting cascade components and along with increased 






Due to the pathophysiological changes and challenges SCD patients are exposed to numerous 
complications of multiple organ systems. The common complications, incidence, clinical consequences 
and salient features are discussed in Table 3.1,4,6,13–19 
Table I Complications of sickle cell disease 




58-70% Severe pain with 
significant morbidity 
- Lasts minutes to 
hours 
- Analgesic control 
difficult 
Most common reason for 
hospital admission. 
Frequency of admission 
indicates disease severity. 
High incidence in: 
- Homozygous variant 
- High Haematocrit 
- Low Haemoglobin F 
- Nocturnal hypoxaemia 
- Sibling history of asthma 
Pulmonary 
Acute Chest Syndrome 
(ACS) 
  











- Pulmonary infection  
- Fat embolism  
- Intravascular pulmonary 
sequestration of sickled erythrocytes  
CXR features: 
New pulmonary infiltrate, consistent 
with alveolar consolidation 










- NO dysregulation 
Screening: 
- Echo: Tricuspid 
regurgitant velocity 




Major risk factor: 
Severity of Haemolytic Anaemia 
Markers of Haemolysis: 
- Low steady state haemoglobin  
- High lactate dehydrogenase  
- High bilirubin  
- High reticulocyte 
Other Causes: 
Iron overload  
Hepatitis C  
Porto-PH 
Thrombo-embolism 
Chronic renal failure 
Recurrent ACS 
Reactive Airway Disease  53% incidence from 
birth to 9yr age 
Restrictive ventilatory 
impairment 
- Mild reduction in 
Total lung capacity 
- Reduced diffusion 
capacity for carbon 
monoxide 
Worsening with age  
 
Leads to increased Pulmonary artery 
pressure in the long term 
Cardiac 
Left ventricular (LV) 
dilation / hypertrophy & 
Diastolic dysfunction 
 
13% Diastolic dysfunction  
- Independent 
predictor of mortality 
- Risk ratio of Death: 
3.5; with Pulmonary 
Hypertension: 12.0  
Chronic Anaemia cause: 
- Increased LV stroke volume, 
increase cardiac output & heart rate 
- LV dilatation may develop and 
progress to LV hypertrophy, 
decreased LV filling and diastolic 
dysfunction 
Arrhythmias 50% Ventricular 
arrhythmia 
38% QT prolongation 
 Occurs during VOC 
Acute right ventricular 
failure 
 
13% Acute rise in pulmonary 
vascular pressure 
Due to VOC or ACS 
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Complication Incidence Clinical Consequence Features 
Renal 
Renal impairment 30% Sickling and vaso-






Erythrocyte predisposed to sickling 
in the renal circulation due to: 
- Low flow state 
- Low partial pressure and  
- High oxygen extraction  
- Low pH  
- High osmolality leading to 
cellular dehydration 
Recurrent UTI Common  Haematuria, 
proteinuria, fever 











Transfusion to achieve 
HbS<30% reduce risk 
by 90%  
Predisposed to CVA due to: 
- Anaemia  
- Leucocytosis 
- Hypoxaemia  
- Abnormal rheology causing 
endothelial damage 
- Functional NO deficiency 
associated with haemolysis 
Impaired regulation of blood flow 





2nd & 3rd most common All ages, most common 
in 20-30yr old 
26% mortality in two weeks 
Immunological 









improve prognosis & 
outcome  
 
Predisposed to systemic infection 
due to: 
- Impaired splenic function 
- Defect in complement 
activation 
- Micronutrient deficiency 
- Tissue ischaemia 
Auto- or 
alloimmunization 
Common Allo-immunisation  
Haemolytic transfusion 
reactions 
A consequence of recurrent 
erythrocyte transfusion  
Haematological  
Acute aplastic crisis 
 
Common Major suppression of 
Erythropoiesis 
Parvovirus B19 infections trigger 










Acute drop in Hb 




Common Functional asplenism 
Result in infections at 
unusual sites: 
- Osteomyelitis  
- Splenic abscesses 
Increased risk of systemic bacterial 
infection due to: 
- Defects of opsonisation  
- Phagocytic dysfunction  






Hydroxyurea combined with regular transfusion and iron chelation are commonly used in the management 
of SCD patients. Stem cell transplant and gene therapy are used in selected patients.4 These topics will not 
be discussed in depth in this literature review. 
3.4 General Perioperative considerations 
 
The aim of the preoperative evaluation is to identify risk factors, assess the extent of end organ damage 
and optimise existing organ dysfunction (Table II). An individualised perioperative management plan is 
then developed to prevent or limit the potential triggers for sickling. (Table III) 6,19 
 
Table II SCD patient presenting for surgery – Risk factors and preoperative considerations 
Predictors of complications Categories / Features Planning / Intervention 
Type of Surgery 20 Low, moderate or high 
risk surgery 
Right surgery for the right 
patient 
Disease activity and 
progression of target organ 
damage 21 




Actively seek evidence of target 
organ damage and investigate 
with appropriate tests, e.g. CXR 
for ACS 
Progression of Pulmonary 
complications 6 
- Frequency / clustering 
of ACS symptoms 
- Abnormal CXR  
- Preoperative physiotherapy 
- Incentive spirometry 
- Early ambulation 
- Adequate pain control (19) 
Pre-existing or intercurrent 
infection 6 
Triggers for ACS - Treat infection 
- Appropriate antibiotic 
prophylaxis 
- Strict asepsis 
Haplotype 6 More severe disease in 
African haplotypes  
Determine haplotype  
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Table	  III	  Triggers	  of	  erythrocyte	  sickling	  
Triggers for Sickling Considerations 
Deoxygenation 
No clinical data in the surgical or 
anaesthetic literature clearly 
demonstrated hypoxia triggering 
sickling  
Complications occurred even if 
hypoxia was avoided 
Factors affecting oxygen delivery 
Anaemia 
Obstructive or restrictive lung disease 
Ventilation-perfusion mismatch 
Vascular damage 
Abnormal micro-vascular rheology  
Peripheral arterio-venous shunting 
Disturbed NO transport 
Importance of Oxygenation 
Avoidance of anxiolytics, routine hyper-oxygenation or 
prolonged oxygen supplementation has no proven role over 
basic perioperative principals of adequate oxygenation and 
prevention of hypoxia 
Dehydration 
No causal relationship between 
dehydration and the precipitation 
of SCD complications 
In-vitro studies: intracellular 
dehydration results in increased Hb 
concentration and sickling 
 
Maintain adequate cellular hydration during perioperative 
fasting period 
Hypothermia 
Skin chilling triggers VOC 
 
Anaesthesia overrides thermoregulatory mechanisms 
Actively maintain normothermia 
Acidosis 
Acidosis potentiate erythrocyte sickling 
during hypoxia 
 
Managing cardiovascular parameters and fluid status to 
avoid pH imbalances 
Vascular Stasis 
Low flow states, CPB, hypothermia & 
vasoconstriction 
Maintain CO and volume status 
Positioning, pneumatic compression stockings to aid 




Erythrocyte transfusion is indicated to 1.) Prevent and treat complications of SCD, 2.) Correct anaemia or 
3.) Replace blood loss.  
The proposed aims of erythrocyte transfusion in SCD are to increase the haematocrit and reduce the HbS 
concentration. However, there is no consensus on a safe level of Hb or an ideal proportion of HbA and 
HbS. The physiological implications of HbS concentrations of 40% are very different in the non-
transfused SCT patient, compared to the transfused SCD patient. In SCT, each erythrocyte contains 40% 
HbS and 60% HbA. In the SCD patient 40% of the erythrocytes contains HbS only and the remaining 60% 
contains 100% HbA. Each erythrocyte in the SCT patient is more resistant to triggering sickling than the 
SCD patient. 22 
Controversies around perioperative transfusion in SCD exist and the aims of transfusion in this setting are 
not clearly defined. The indications for pre-operative transfusion have been difficult to determine 
conclusively. 
In a retrospective observational review of paediatric patients undergoing 66 surgical procedures without 
preoperative transfusion, Griffin and Buchanan (1993) reported only one episode of ACS and no pain 
crisis after 46 minor procedures. The authors concluded that the risk of SCD complications is low and the 
risk of routine transfusion is not justified in minor procedures.22 
The Cooperative Study of Sickle Cell Disease, a large retrospective review by Koshy et al (1995), reported 
a reduction in SCD related complications in transfused SCA patients for minor surgery. But this study 
included adults and children and did not control for confounding variables. They could also not 
demonstrate any correlation between HbA levels and rate of post-operative complications – except for a 
decrease in pain crisis in those patients with higher HbA levels. Furthermore the effect of transfusion was 
dependent on the type of surgical procedure and patient phenotype. Despite inconclusive evidence of 
benefit they recommended preoperative transfusion to achieve Hb > 10 g/dl without any guidelines to 
ideal HbS concentration.21,22 
The Preoperative Transfusion in Sickle Cell Disease Study Group (1995) investigated the impact of 
different transfusion strategies on outcome variables in SCD requiring surgery. In this multicentre trial 
SCD patients randomly assigned to receive either an aggressive or conservative transfusion regimen prior 
to surgery, were compared. Analysis showed comparable complication rates and a doubling of transfusion 
related complications with the aggressive transfusion regimen.20 Table IV summarise their findings. 
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Table IV Complications of pre-operative blood transfusion: Aggressive and Conservative regimen 




Aggressive  HbS < 30% 31% 14% 
Conservative Hb > 10g/dl 34% 7% 
 
In 1999 the same group published results of 118 patients (adults and children) undergoing elective 
orthopaedic surgery. Again the perioperative complication rate between the aggressive or conservative 
transfusion groups did not differ and no advantage could be demonstrated.23 
Duke University published a 10-year retrospective study (1998) investigating the beneficial effect of 
preoperative transfusion in major surgery. The transfusion regime was in keeping with the Aggressive 
transfusion approach of Vichinsky et al, with the aim to reduce the HbS concentration < 30% over 3-4 
weeks prior to surgery. The authors recognised the limitations of this retrospective review to pick up 
complications but recommended to transfuse SCD patients for major surgery preoperatively since the 
proposed benefits outweigh the risks.19,24 
A review from the Cochrane Library database in 2001 set out to investigate the relative risks of 
preoperative transfusion in SCD patients, undergoing any type of surgery in any setting. Only one study 
met their criteria.(20) Recommendations for subgroups could not be made on the basis of available 
evidence and need for further randomised studies were expressed.25 
The Transfusion Alternatives Preoperatively in Sickle Cell Disease study (TAPS), a multi-centre, 
randomized trial (2013), investigated whether perioperative complications are altered by preoperative 
transfusion. Groups were randomized to receive no transfusion or preoperative red cell transfusion to 
achieve Hb concentration > 10g/dl. Patients in the transfusion group who had an Hb < 9g/dl, received a 
top-up transfusion. Those with Hb > 9g/dl had a partial exchange transfusion to achieve an estimated HbS 
concentration below 60%. The majority of patients (97%) had SCA. Ten out of the eleven serious adverse 
events (91%) where ACS, nine of which was in the non-transfused group. The authors concluded that 
preoperative transfusion of SCA patients undergoing medium risk surgery is beneficial and reduces the 
risk of perioperative complications.26 
Although widely practiced, prophylactic preoperative erythrocyte transfusion remains a treatment with 
significant potential risks and needs to be individualized for each patient in a multi-disciplinary team - 
surgeon, anaesthesiologist, intensive care physician and haematologist. 
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3.5 Perioperative considerations for cardiac surgery 
 
The patient with coexisting SCD presenting for cardiac surgery requiring cardiopulmonary bypass creates 
numerous challenges. High-risk surgery and exposure to a multitude of potential triggers for sickling - low 
flow states, aortic cross clamping, hypothermia, cold cardioplegia solution and potential for acidosis - 
requires careful consideration.  
 
Transfusion  
The benefit of perioperative transfusion for high-risk surgery was discussed and is accepted practice for 
patients undergoing cardiac surgery. However, there is no consensus on whether to transfuse pre-
operatively or intra-operatively, or what the transfusion targets are. The approach to transfusion varies 
between institutions and a number of studies and case series/reports describe the safe use of preoperative 
exchange transfusion or intra-operative exchange transfusion going onto CPB, or a combination of 
both.5,9,22,27–29 The latter can be either complete exchange transfusion (whole blood volume is drained from 
the venous catheter prior to CPB) or partial, which involves separating the whole blood sequestered from 
the patient into the three components. The erythrocytes are discarded, whilst plasma and platelets are 
transfused back to patient at the completion of CPB.22,30 
The potential benefits of exchange transfusion performed with the CPB alone, without preoperative 
exchange, include reduction in costs, hospital stay, the number of invasive procedures, and exposure to 
autologous blood units, with no evidence of increased perioperative complication rates.22 The distress of 
preoperative transfusion and interventions to patient and family members are also avoided.29 Yousafzai et 
al recently published a case series of 47 patients (43 SCA and 4 SCT) undergoing cardiac surgery 
requiring CPB. Their retrospective review included 21 paediatric patients who received either preoperative 
or intraoperative exchange transfusion, or both. Intra-operatively a haematocrit of 30% and an HbS < 10% 
was targeted using a combination of RBC, crystalloid and colloid CPB prime, the volume of which was 
calculated using the patients age, weight and body surface area (BSA). The prime was oxygenated  
to > 50kPa before initiation of CPB and maintained during bypass. Furthermore, venous oxygen saturation 
was maintained between 75%-80% and a pH of 7.34-7.44. Of these cases none developed sickling. 
Reported postoperative complications included exploration for haemorrhage in 3 patients (6.4%), stroke in 
2 patients (4.3%), renal failure in 2 patients (4.3%), and prolonged ventilation in 1 patient (2.1%) 9,22  




Preparation of blood products 
The implications of alloimmunisation are important to consider when preparing a SCD patient for major 
surgery. Alloimmunisation is the most common complication associated with aggressive preoperative 
transfusion (to achieve an HbS<30%) and the incidence is twice as high compared to a conservative 
transfusion protocol (Hb>10g/dl). There is a strong association with the number of units transfused. The 
reported incidence of alloimmunisation after receiving multiple transfusions is higher in SCD patients 
when compared to the general population (8-38% vs. 2%).20 This may be related to the phenotypic 
incompatibility between the predominantly black SCD patients and the predominantly white donors 
described in European and American literature. A recent article presented data suggesting significantly 
lower rates of alloimmunisation (6.1%) amongst a more homogenous Ugandan population of blood donors 
and SCD recipients.22,31 It may be that matching blood to race or specific antigens may decrease the 
patient’s susceptibility to alloimmunisation. Additionally, when limited phenotypic matching for the most 
common erythrocyte antigens (C, E and K) are used the incidence of transfusion related complications 
decrease.22,32 A single centre data comparison found that C, E, D, Kell, Kidd, and Fya are the critical 
antigens to match and dramatically minimized alloimmunisation. The recommendations from this research 
were recently introduced in the management of SCD patients at RCWMCH.33 Lastly, it is postulated that a 
chronic inflammatory state plays a role in developing alloimmunisation, and may contribute to the 
increased incidence seen in SCD.32 
 
Temperature regulation and Cardioplegia 
Since hypothermia is associated with an increased risk of sickling events the use of hypothermia during 
CPB in SCD is controversial. Normothermia or mild hypothermia is proposed, though some authors 
suggest that moderate hypothermia is safe and even deep hypothermic arrest can be employed with 
success.9, 22,27,29,34,35 
Another consideration is the use of cold cardioplegia transfused into the coronary vasculature and the risk 
inducing sickling of RBC and vaso-occlusion. The approaches to limit these events vary with some 
authors suggesting the use of crystalloid cardioplegia rather than blood cardioplegia to avoid introducing 
erythrocytes that may sickle into the coronary vessels.30,36 The temperature of the cardioplegia solution is 
also debated and some authors advocate an initial transfusion of warm blood or crystalloid cardioplegia, 




Tranexamic acid  
Cardiac surgery requiring CPB and induced hypothermia has the potential to activate the fibrinolytic 
system. In particular when the blood-artificial surface interaction within the bypass circuit activates 
thrombin and subsequently lead to initiation of fibrinolysis. This process is not fully suppressed by 
heparinisation, therefore prophylaxis and treatment of hyperfibrinolysis is important during cardiac 
surgery involving CPB. The synthetic lysine analogues, tranexamic acid and epsilon-aminocaproic acid, 
act by reversibly blocking the lysine binding sites of plasminogen, thus preventing its activation to 
plasmin, and therefore stopping the lysis of polymerised fibrin. It is effective in reducing blood loss, and 
retrospective data seem to suggest that tranexamic acid might be more beneficial than epsilon-
aminocaproic acid.37,38  
The use of anitfibrinolytics during CPB in SCD patients has not been evaluated but a number of case 
reports on its use have not shown any detrimental effect.5,9 
 
Postoperative Care 
There are no literature or guidelines for the post-operative care of SCD following cardiac surgery. Apart 
from the accepted standard of care, the aims remain avoidance of factors that could potentially provoke 
erythrocyte sickling - adequate analgesia and avoiding hypoxia, acidosis, hypothermia and dehydration are 
key to the uneventful management of these patients.  
 
3.6 Conclusion 
SCD patients requiring CPB for corrective cardiac surgery is a unique and challenging clinical scenario 
with numerous anaesthetic considerations. Apart from the impact of surgery, CPB exposes the patient to 
circumstances that may trigger HbS polymerization and sickling. The aims of perioperative management 
are to avoid or limit the potential for these conditions to cause complications.  
Perioperative transfusion to achieve Hb levels >10 g/dl and HbS concentration < 30% is advocated and 
this can be achieved pre- or intra-operatively (going onto bypass). High normal CPB flow, mean arterial 
pressure, and high arterial and venous oxygenation is also commonly employed to maintain perfusion and 
oxygenation, and prevent acidosis. Mild to moderate hypothermia is acceptable and does not seem to 
impact on outcome. Extended antigen cross matching dramatically decreases the incidence of 
alloimmunisation and is essential in SCD who may require multiple transfusions in their lifetime.  
A well conducted general anaesthetic in a multidisciplinary team with due consideration of the common 
complications is essential for optimal patient outcome. 
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Sickle cell disease (SCD) is the most common inherited haematological disorder, producing a mutation of 
the haemoglobin molecule known as haemoglobin S (HbS). The presence of HbS in the erythrocyte makes 
it prone to sickling - a process which may lead to vaso-occlusive injury, haemolysis and a hypercoagulable 
state. Sickling is precipitated by dehydration, hypoxia, hypothermia, acidosis and low flow states. Over 
time, multi-organ damage develops with significant morbidity and mortality. 
Paediatric patients with SCD and congenital heart defects may require anaesthesia for corrective cardiac 
surgery on cardiopulmonary bypass (CPB). During the perioperative period these high-risk patients may 
suffer significant complications when exposed to the conditions that favour erythrocyte sickling.   
This case series details our experience of four paediatric patients with SCD patients who underwent 
corrective cardiac surgery at Red Cross War Memorial Children’s Hospital. The pathophysiology is 
discussed and the perioperative management of transfusion, cardiopulmonary bypass and temperature 
regulation is highlighted.  
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Patients with sickle cell disease (SCD) presenting for cardiac surgery requiring cardiopulmonary bypass 
(CPB), pose a unique perioperative challenge when exposed to conditions that can elicit erythrocyte 
sickling with potentially fatal complications. 
Literature on the optimal management of these patients is limited, and most contributions on this topic are 
retrospective case reports or small series.1,2 In this case series and discussion we endeavour to heed the 
call by Mennes et al: “To increase the available evidence, every experience with cardiac surgery in sickle 
cell disease patients should be reported.” 3 
 
Methods 
Following approval from the Departmental Research Committee and the University of Cape Town 
Research Ethics committee, a retrospective review of data on patients with SCD who underwent cardiac 
surgery was conducted.  Four patients were identified between April 2004 and May 2013.  A total of seven 
cardiac surgical procedures were performed in these four patients, six procedures requiring CPB. In the 
decade preceding this review, only one patient with SCD underwent cardiac surgery. 
Relevant patient information and clinical parameters were collected from the patient records and analysed.  
 
Anaesthetic management 
Perioperative management differed between patients. A description of the management principles for 
these cases is discussed and pertinent information highlighted.  
Patients were prepared and optimized for surgery in the Paediatric Intensive Care Unit (PICU) in 
collaboration with the surgeons, cardiologists, haematologists and intensivists involved. Regular 
medication was continued until the day of surgery. Oral intake was stopped four hours prior to surgery and 
intravenous fluid, calculated according to body weight, was initiated. Sedative premedication was not 
routinely administered. Red cell transfusion prior to surgery was individualized for each patient. 
Anaesthesia was induced with inhalation of a Sevoflurane and oxygen mixture and after intravenous 
access was established, Fentanyl (5-10mcg/kg) and Pancuronium (0.1mg/kg) was administered. Following 
tracheal intubation, anaesthesia was maintained with 1% Isoflurane in oxygen and air. Incremental doses 
of Fentanyl (up to 25mcg/kg) were given.   
 32 
Invasive monitoring, arterial line and central venous access, was inserted once the patient was deeply 
anaesthetized. Prophylactic antibiotics were given prior to surgery and repeated four hourly. Heparin 300-
400units/kg was administered prior to bypass and Activated Clotting Time (ACT) was monitored to 
achieve a value > 480 seconds. 
Arterial blood pressure, central venous pressure, electrocardiogram, saturation with pulse oximetry and 
rectal temperature was routinely monitored during and after surgery. Cerebral near infrared spectroscopy 
(NIRS) was introduced as routine monitoring for cardiac patients in 2007. Patients were transferred to the 
ICU intubated, and infusions of midazolam and morphine were initiated to achieve sedation and analgesia. 
Patients were monitored in the ICU and weaned from ventilation and extubated once hemodynamic, 
pulmonary and cognitive function was optimized.  
 
Cardiopulmonary Bypass 
The bypass circuit was primed with a combination of crystalloid, colloid and red blood cells to achieve a 
haematocrit level of 30%. 2000 units heparin, 10ml of sodium bicarbonate and 4ml calcium gluconate per 
unit blood were added to the prime solution. The prime was oxygenated to >50kPa before bypass was 
initiated and maintained throughout the procedure, while venous oxygen saturation was kept at or above 
80%. Patients were cooled to between 32 – 34 degrees Celsius. Arterial pH was kept between 7.34 and 
7.44. Full flow was calculated using the patient’s height and weight. Routine cardioplegia at this time was 
crystalloid St. Thomas solution. 
 
Results 
All patients were immigrants from central Africa undergoing corrective cardiac surgery for congenital 
heart disease (CHD). Of the seven procedures performed, two required redo-surgery following breakdown 
of the Ventricular septal defect (VSD) patch.  Respiratory complications were limited to one episode of 
collapsed consolidation of the left lung requiring prolonged ventilation. None of the patients developed 
acute chest syndrome (ACS). Three cases had co-existing pulmonary hypertension (PH). In case 1 
symptoms resolved following surgery, but in case 2 it persisted. The PH in the latter possibly developed 
due to a combination of longstanding severe SCA and not because of the congenital heart lesion alone.  
Data on cooling on CPB was incomplete. Of interest case 4, performed in 2013, was cooled to 34°C. This 




A limitation of retrospective data collection from patient folders is that key information is not available or 
was not performed. For instance it is not clear whether perioperative HbA/HbS concentrations was 
monitored, or when erythrocyte transfusion was performed. Cases 1 and 4 had preoperative HbS 
concentrations of 97% and 48% respectively. Both these patients had pre-operative exchange transfusions. 
All patients had intra-operative transfusion at initiation of CPB. See Table I. 
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The global number of SCA newborns reached 305 800 in 2010, with Sub-Saharan Africa (SSA) 
accounting for 79% of the total.2 The incidence in South Africa (SA) remains low, but recently a sharp 
increase (300%) was demonstrated in research at Red Cross War Memorial Children’s Hospital 
(RCWMCH). This is likely due to the changing population demographics and immigration from Central 
African countries where the disease is most prevalent.8 The global prevalence of SCD is predicted to 
increase and along with improved screening programs, diagnostic and treatment modalities, more patients 
with SCD may require cardiac surgery in the future.9 
Genetics 
 34 
Sickle cell disease (SCD) is the most common monogenic disease in humans and also the most common 
inherited haematological disorder.8,10 The affected gene is located on chromosome 11, which codes for the 
β-globin chain of HbA. A single point mutation on this gene results in the β−globin chain losing part of its 
negative charge, changing the solubility and stability of the depicted Ηb molecule. The Hb constructed of 
this mutated β−globin chain (Figure 1) is referred to as haemoglobin S (HbS)3,11,12  
 
Figure 1 Formation of Haemoglobin A, S and F 
 
Inheritance is autosomal recessive. The homozygous phenotype is known as sickle cell anaemia (SCA) 
and contains HbS (80-98%) and some HbF. The heterozygous phenotype contains normal HbA (60-65%), 
HbS (35-40%) and some HbF, and is referred to as sickle cell trait (SCT). See figure 2. SCA present with 
more frequent symptoms and the disease process may be severe and progressive.3,10,12,13  
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In affected individuals erythrocytes may sickle when the HbS it contains becomes deoxygenated leading 
to a conformational change and polymerization of the Hb molecule. This stiffens and disrupts the 
erythrocytes structural integrity (“sickling”) making it less pliable and more prone to aggregation, vascular 
occlusion and haemolysis. The degree of polymerization and sickling is dependent on two aspects: the 
duration of deoxygenation and the total HbS concentration. Hypoxia, hypothermia, acidosis and low flow 
states are classically described triggers for sickling. However, recent research suggests that more complex 
processes are at play.3  
Following erythrocyte sickling and vascular occlusion, secondary endothelial inflammation, activation of 
coagulation and increased expression of adhesion molecules such as vascular adhesion molecule-1 
(VCAM-1), P-selectin and E-selectin leads to progressive micro-vascular occlusion. When blood flow to 
the affected tissues is restored, reperfusion injury occurs with characteristic free radical production, 
oxidant stress and the release of platelet activating factor (PAF). Repetitive cycles of ischemia-reperfusion 
injury lead to multi-organ failure associated with SCD.10,13,14 
Haemolysis can lead to clinically significant anaemia, but also contributes to endothelial inflammation 
through the release of haemoglobin (Hb) and arginase-1 into the plasma.12 Free plasma Hb scavenges 
nitric oxide (NO) while arginase-1 metabolizes the NO precursor, L-arginase, leading to endothelial 
dysfunction and worsening micro-vascular disruption.3,14 
Dysregulation of coagulation leads to a hypercoagulable state in SCD. Activation of platelets, tissue factor 
and increased platelet numbers are some of the aspects involved.12,15–17 See Figure 3.
 













Over time, due to the process of ischaemia-reperfusion, haemolysis and hypercoagulability, a multisystem 
disease develops with numerous complications. These are listed with the associated features  
in Table II.10,12,13,15,17–23 
Table	  II	  Complications	  of	  sickle	  cell	  disease	  
Complication Features 
Vaso-occlusive crisis (VOC)  
 
Severe painful episodes associated with vaso-occlusion 
High incidence in: 
- Homozygous variant 
- High Haematocrit 
- Low Haemoglobin F 
- Nocturnal hypoxaemia 
- Sibling history of asthma 
Pulmonary 
Acute Chest Syndrome (ACS) 
  
Causes: 
- Pulmonary infection  
- Fat embolism  
- Intravascular pulmonary sequestration of sickled 
erythrocytes  
Chest X-ray features: 
- New pulmonary infiltrate, consistent with alveolar 
consolidation involving at least one complete lung 
segment 
Pulmonary Hypertension (PH) 
 
Major risk factor: 
Severe Haemolytic Anaemia 
Markers of haemolysis: 
- Low steady state haemoglobin  
- High lactate dehydrogenase  
- High bilirubin  
- High reticulocyte 
Other Causes: 
- Iron overload  
- Hepatitis C  
- Porto-Pulmonary hypertension 
- Thrombo-embolism 
- Chronic renal failure 
- Recurrent ACS 
Reactive Airway Disease  Worsening with age  
Results in increased pulmonary artery pressure 
Cardiovascular 
Left ventricular (LV) 
dilation/hypertrophy & Diastolic 
dysfunction 
 
Consequences of chronic anaemia  
- Increased LV stroke volume, increase cardiac output & 
heart rate 
- LV dilatation may develop and progress to LV 
hypertrophy with decreased LV filling and diastolic 
dysfunction 
Arrhythmias  May develop during vaso-occlusive crisis 
Acute right ventricular failure Secondary to vaso-occlusive crisis or acute chest syndrome 
Renal 
Renal impairment Erythrocyte predisposed to sickling in renal circulation due to: 
- Low flow state 
- Low partial pressure oxygen 
- High oxygen extraction  
- Low pH  
- High osmolality leading to cellular dehydration 





Cerebrovascular accident (CVA) Conditions that predispose SCD patients to CVA: 
- Anaemia  
- Leucocytosis 
- Hypoxaemia 
- Abnormal rheology causing endothelial damage 
- Functional NO deficiency associated with haemolysis 
- Impaired regulation of blood flow causing hyperaemia  
Subarachnoid- & Intracranial 
haemorrhage 
 
- 26% mortality in two weeks 
Immunological 
Infection Prone to infection due to: 
- Impaired splenic function 
- Defect in complement activation 
- Micronutrient deficiency 
- Tissue ischaemia 
Auto- or alloimmunization Common complication of recurrent erythrocyte transfusions 
Haematological 
Acute Aplastic Crisis Parvovirus B19 infections trigger acute, severe exacerbations of 
anaemia  
Haemolytic crisis Acute anaemia often requiring erythrocyte transfusion 
Splenic sequestration crisis Require elective splenectomy when acute phase resolved 
Auto-infarction of Spleen  Increased risk of systemic bacterial infection due to: 
- Defects of opsonisation  
- Phagocytic dysfunction  
- Decreased cell-mediated immunity 
  
Treatment 
Treatment of SCD frequently involves erythrocyte transfusion which increases total Hb concentration, 
enhance oxygen delivery and improve tissue oxygenation. It also decreases the endogenous erythropoiesis 
and in this way reduces the HbS production. This has been shown to decrease complications associated 
with SCD, but acute transfusion reactions and alloimmunisation risks are increased.3,12,22–24 
Common indications include:   
• Acute symptomatic anaemia 
• Aplastic crises 
• Acute sequestration crises by the spleen or liver 
• Stroke 
• ACS 
Medical management of SCD with hydroxyurea increase HbF concentration and has shown to decrease 
the frequency of painful episodes, ACS, the need for blood transfusion and admission to hospital. Stem 




Perioperative considerations  
 
Preoperative assessment and preparation 
A thorough history and examination is essential to evaluate disease severity and the extent of end-organ 
damage. SCA is more severe than SCT, as is the African haplotype compared to the Asian. Frequency of 
painful symptoms, ACS and hospital admissions are associated with increased risk of perioperative 
complications. Inter-current infection needs to be excluded as this can trigger sickling events and ACS. 
Appropriate special investigations should be directed by the clinical suspicion of complications and end 
organ-damage (Table II). Recent blood test for Hb-level, urea-electrolytes-creatinine, Chest X-ray (CXR), 
urine dipsticks would be appropriate for most cases.3,22 
Special considerations:  
• Pulmonary hypertension is increasingly recognized as a perioperative risk factor and poor 
prognostic indicator.17,25 
• Hydroxyurea treatment may cause bone marrow suppression. If suspected, discuss with a 
haematologist.22 
• Order blood products well in advance. The blood bank needs to perform extended antigen 
matching.  
• Discuss the case with the cardiac surgeon, perfusionists and intensivists, and enquire about 
particular steps, i.e. pre-operative transfusion, intra-operative cooling, post-operative plan. 
• Inform ICU, determine availability of beds. 
Being mindful of the common precipitants of sickling may help in planning the perioperative care of the 
patient. As a general rule keep the patient warm, well hydrated and comfortable throughout this period. 
 
Transfusion and Cardiopulmonary bypass 
Perioperative erythrocyte transfusion has been shown to decrease complications such as ACS, and is 
accepted practice for all SCD patients undergoing major surgery. A recent randomized control trial (RCT), 
confirmed these findings particularly in the SCA patients, although cardiac surgery was excluded in their 
protocol.24,26 A transfusion-free cardiac surgery has not been described in SCD as yet and is therefore not 
recommended.3  
Whether to transfuse patients pre- or intra-operatively, or what the end points of transfusion should be, is 
not clear.4 The bulk of the literature reports pre-operative transfusion, either as an exchange transfusion or 
“top-up” transfusion to adjust Hb levels and HbS concentration.   
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Most often the goals aimed to achieve a Hb > 10g/dl and/or HbS < 30%. An increase in adverse 
transfusion reactions is reported when the latter is targeted.27 A case series on three paediatric patients 
with SCD undergoing corrective cardiac surgery describes the use of intra-operative exchange transfusion 
only at the start of bypass, without any adverse events.7 The authors concluded: “We also eliminated the 
potential harm and distress for the children and their families associated with a pre-operative exchange 
transfusion, which itself carries significant risks without any major reduction in the likelihood of a sickle 
cell crisis during surgery.”  
The patients in our series often required pre-operative transfusion to manage the acute disease and not as a 
prophylactic measure prior to surgery. 
The largest case series of 47 SCD patients included 21 paediatric patients who received either pre-
operative or intraoperative exchange transfusion, or both. Intra-operatively a haematocrit of 30% and an 
HbS < 10% was targeted using a combination of RBC, crystalloid and colloid CPB prime, the volume of 
which was calculated using the patients age, weight and body surface area (BSA). The prime was 
oxygenated to > 50kPa before initiation of CPB and maintained during bypass. Venous oxygen saturation 
was maintained between 75%-80%, with a targeted pH of 7.34-7.44. Of these cases, none developed 
sickling.1,4 This approach seems to combine the benefits of perioperative transfusion and appropriate CPB 
setup effectively to limit the potential for adverse events.   
At RCWMCH a similar approach to the one described above was followed. 
The principle of perioperative transfusion is to improve oxygen delivery by increasing the HbA 
concentration, and limit sickling potential by decreasing HbS concentration. Whether a SCD patient is 
transfused pre-or intra-operatively will depend on their current clinical condition and local protocol. The 
sickling risks are much lower in SCT patients and intra-operative transfusion alone may be a safe option.  
 
Allo-immunisation 
Erythrocyte allo-immunisation is the most common transfusion related complication in SCD patients and 
may lead to life threatening haemolytic disease in the foetus and newborn (HDFN), acute haemolytic 
transfusion reactions (AHTR), and delayed haemolytic transfusion reactions (DHTR). A higher rate of 
allo-immunisation after multiple transfusions is seen in SCD when compared to the general population. 
This may be due to phenotypic incompatibility between the predominantly black SCD patients and the 
predominantly white donors described in European and American literature. Indeed, the incidence in 
Uganda, Nigeria and Jamaica is much lower, where racial antigenic homogeneity between donors and 
recipients is greater.4,27–30  
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Recent research showed that extended donor/recipient matching reduces alloimmunisation significantly. A 
large single centre study found that specifically matching C, E, D, Kell, Kidd, and Fy-a antigens 
dramatically decreased the incidence. Subsequently, the provincial Blood Transfusion Service made 
recommendations to perform extended antigen matching for all SCD patients and to issue the closest 
phenotypically matched blood available.31 This process may take longer, and blood products should be 
ordered well in advance to avoid delays in issuing the matched blood products. 
Allo-immunisation in a SCD patient is potentially catastrophic and all efforts should be made to minimize 
the risk. Ordering extended antigen-matched blood products timeously, and administering it appropriately, 
should be a priority during the perioperative care of the SCD patient. Every effort should be made to avoid 
a transfusion reaction in a patient with an existing haematological disease, like SCD. It is advisable to 
discuss the patient with the haematologist and blood bank prior to surgery.  
 
Cooling and Cardioplegia 
Hypothermia, theoretically, predisposes HbS to polymerization and vasoconstriction which may potentiate 
sickling and vaso-occlusion. Although the most recent publications report cooling to between 32-34°C 
without adverse events, hypothermic CPB and deep hypothermic arrest have been used with success in 
SCD patients.1,4,7,32-34 The benefits of cooling during CPB needs to be weighed against potential 
complications of sickling due to hypothermia. For the reasons described above, the use of cold 
cardioplegia solution raises concern. The use of initial warm crystalloid cardioplegia (26-32°C) to flush 
out residual erythrocytes, followed by cold cardioplegia solution, is advocated.3–6 
The concerns of cooling and cardioplegia should be considered on a case-to-case basis and is best 
discussed with the cardio-thoracic surgeon and perfusionist prior to CPB. Depending on the cardiac lesion, 




The use of anti-fibrinolytics, such as tranexamic acid, has not been validated for SCD patients requiring 





The goal to avoid sickling or limit triggering conditions is followed through into the post-operative care 
phase. To maintain continuity of care, these aims should be clearly communicated with the ICU staff and 
surgical team.  
Transfusion triggers should be discussed and clearly stated in the post-operative orders. Order blood 
products in advance to ensure that extended matching can be done by blood bank. Close monitoring is 
essential and if complications occur, these may be due to ACS or other complications related to SCD and 
not necessarily due to the surgery.  
Adequate pain management is essential to ensure patient comfort and avoid conditions that may 
predispose patients to sickling.3 A combination of opiates and paracetamol is usually sufficient. If pain 
remains difficult to control post-operatively, it may be due to an episode of VOC or chronic pain related to 
SCD. Other analgesic modalities may need to be considered.12 
Table III summarises the perioperative considerations. The acronym “SCD-CPB” may be helpful to 
remember these. 
 
Table	  III	  Sickle	  cell	  disease	  and	  cardiac	  surgery:	  Perioperative	  considerations	  in	  a	  nutshell	  
  
S Is the patient SCT or SCA? What is the HbS concentration? 
C What Complications and end-organ damage exist? 
D Discuss the patient with haematologist/surgeons/perfusionist/intensivist 
  
C Cardioplegia – preferably blood cardioplegia / Cooling 32-34°C 
P Precipitants of Sickling: hypoxia/hypothermia/acidosis/low flow conditions/dehydration 





Over the last decade, major cardiac surgery was performed safely in high-risk SCD patients at RCWMCH. 
To minimise the potential for erythrocyte sickling and adverse events in these patients, a thorough 
understanding of the pathophysiology and complications are essential. In each case the implications of 
erythrocyte transfusion, cardiopulmonary bypass, cardioplegia and cooling, require special consideration 
and discussion with the surgeon, perfusionist and intensive care physician. More research and publications 
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